Literature DB >> 19286484

Differential stabilities of alternative exon-skipped rod motifs of dystrophin.

Chris Ruszczak1, Ahmed Mirza, Nick Menhart.   

Abstract

Exon skipping repair is a strategy being investigated in early stage clinical trials to treat Duchenne muscular dystrophy. This is most applicable to the majority of cases which arise when genetic defects cause frame shift mutations, and induced exon skipping of out-of-phase exons restores the reading frame. However, the consequences to the edited protein so produced have not been considered. In many cases alternative routes to restoring the reading frame are possible, and we show in a test case involving exon 44 that the resulting differently edited proteins greatly vary in stability, with one of them very similar to normal unskipped dystrophin, and the other much less stable as assessed by the thermodynamics of folding as well as resistance to proteolysis. This has implications for the design of optimal therapeutic exon skipping strategies, which presumably wish to result repairs with as much fidelity to normal dystrophin as possible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286484      PMCID: PMC2696117          DOI: 10.1016/j.bbapap.2009.02.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  39 in total

1.  Partly folded states of members of the lysozyme/lactalbumin superfamily: a comparative study by circular dichroism spectroscopy and limited proteolysis.

Authors:  Patrizia Polverino de Laureto; Erica Frare; Rossella Gottardo; Herman Van Dael; Angelo Fontana
Journal:  Protein Sci       Date:  2002-12       Impact factor: 6.725

Review 2.  Probing protein structure by limited proteolysis.

Authors:  Angelo Fontana; Patrizia Polverino de Laureto; Barbara Spolaore; Erica Frare; Paola Picotti; Marcello Zambonin
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

3.  Interaction of dystrophin rod domain with membrane phospholipids. Evidence of a close proximity between tryptophan residues and lipids.

Authors:  Elisabeth Le Rumeur; Yann Fichou; Sandrine Pottier; François Gaboriau; Corinne Rondeau-Mouro; Michel Vincent; Jacques Gallay; Arnaud Bondon
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

4.  Protein stability curves.

Authors:  W J Becktel; J A Schellman
Journal:  Biopolymers       Date:  1987-11       Impact factor: 2.505

5.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

6.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

7.  Human Gene Mutation Database (HGMD): 2003 update.

Authors:  Peter D Stenson; Edward V Ball; Matthew Mort; Andrew D Phillips; Jacqueline A Shiel; Nick S T Thomas; Shaun Abeysinghe; Michael Krawczak; David N Cooper
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

8.  Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside.

Authors:  Cornel Badorff; Kirk U Knowlton
Journal:  Med Microbiol Immunol       Date:  2003-08-12       Impact factor: 3.402

Review 9.  Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

Authors:  Francesco Muntoni; Silvia Torelli; Alessandra Ferlini
Journal:  Lancet Neurol       Date:  2003-12       Impact factor: 44.182

10.  Genomic definition of a pure intronic dystrophin deletion responsible for an XLDC splicing mutation: in vitro mimicking and antisense modulation of the splicing abnormality.

Authors:  Francesca Gualandi; Paola Rimessi; Barbara Cardazzo; Luisa Toffolatti; Matthew G Dunckley; Elisa Calzolari; Tomaso Patarnello; Francesco Muntoni; Alessandra Ferlini
Journal:  Gene       Date:  2003-06-05       Impact factor: 3.688

View more
  12 in total

1.  Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation.

Authors:  Davin M Henderson; Ann Lee; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 2.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

3.  Internal deletion compromises the stability of dystrophin.

Authors:  Davin M Henderson; Joseph J Belanto; Bin Li; Hanke Heun-Johnson; James M Ervasti
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

4.  Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics.

Authors:  Christine Carag Krieger; Nishant Bhasin; Manorama Tewari; Andre E X Brown; Daniel Safer; H Lee Sweeney; Dennis E Discher
Journal:  Cytoskeleton (Hoboken)       Date:  2010-11-10

5.  Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.

Authors:  Andrew R Findlay; Nicolas Wein; Yuuki Kaminoh; Laura E Taylor; Diane M Dunn; Jerry R Mendell; Wendy M King; Alan Pestronk; Julaine M Florence; Katherine D Mathews; Richard S Finkel; Kathryn J Swoboda; Michael T Howard; John W Day; Craig McDonald; Aurélie Nicolas; Elisabeth Le Rumeur; Robert B Weiss; Kevin M Flanigan
Journal:  Ann Neurol       Date:  2015-03-02       Impact factor: 10.422

6.  Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Authors:  Aurélie Goyenvalle; Jordan Wright; Arran Babbs; Vivienne Wilkins; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2012-02-21       Impact factor: 11.454

7.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Missense mutation Lys18Asn in dystrophin that triggers X-linked dilated cardiomyopathy decreases protein stability, increases protein unfolding, and perturbs protein structure, but does not affect protein function.

Authors:  Surinder M Singh; Swati Bandi; Dinen D Shah; Geoffrey Armstrong; Krishna M G Mallela
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin.

Authors:  Surinder M Singh; Justine F Molas; Narsimulu Kongari; Swati Bandi; Geoffrey S Armstrong; Steve J Winder; Krishna M G Mallela
Journal:  Proteins       Date:  2012-02-17

10.  Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy.

Authors:  Ayhan Atmanli; Andreas C Chai; Miao Cui; Zhaoning Wang; Takahiko Nishiyama; Rhonda Bassel-Duby; Eric N Olson
Journal:  Circ Res       Date:  2021-08-10       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.